The industry’s most advanced FASTQ to final report solution for precision oncology NGS testing powered by AI-enabled literature searches and state-of-the-art manual curation.
How our variant interpretation and reporting software supports ESR1 genomic testing through Marsden360, a blood-based test that analyzes 74 genes to detect genetic mutations in ctDNA.
QCI Secondary Analysis is an optional cloud-based service that processes FASTQ files to produce VCF files containing single nucleotide variants (SNV), insertion–deletion mutation (InDel) and structural variant (SV) calls. The module performs quality and adapter trimming, read mapping, deduplication, local realignment, quality control and variant calling and seamlessly connects to QCI Interpret for an integrated and automated FASTQ to report workflow.
QCI Interpret for Oncology is clinical decision support software that combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine curation (AI-powered curation) to enable high-confidence variant interpretation and reporting.
With its latest release, users can now purchase an add-on Reflex license that enables cases processed using QCI Interpret One’s pre-curation service to be seamlessly submitted for full manual curation—without the need to create a new test. This ensures that you can receive full expert review and content for uncurated variants with ease.
A new optional treatment reporting policy allows for the automatic reapplication of prior treatment decisions based on variant and diagnosis-specific history. This feature helps ensure consistency in treatment reporting for somatic workflows. In the associated screen grab, A) shows how users can specify default filters for treatment matching. B) shows how users can manually "unreport" treatment one based on certain criteria.
In the latest release, QCI Interpret now has a Add Gene List(s) button that allows users to upload and dynamically create custom gene list views beyond the existing pre-specified Gene Panels in the new “Gene Views” section of View Settings. Up to five Gene Lists can be added. These enhancements are designed to provide a more customizable and efficient experience. As shown in the screen grab, this feature is available for oncology and hereditary workflows.
Use QCI Interpret for Oncology to group, filter, and prioritize genetic variants from the variant lists. Find actionable mutations in driver genes and match driver alterations with specific drugs allowing personalized therapeutic management. Sort your variants by interpretation type, alteration type, and clinical actionability in search for those that could be used as prognostic and therapeutic biomarkers.
Clinical cases are deeply curated to gather specific evidence for automated computation of an AMP-recommended classification into 4 categories: Tier 1- variants of strong clinical significance (Level of evidence A and B), Tier 2- Variants of potential clinical significance (Level of evidence C and D), Tier 3 –Variants of unknown clinical significance, and Tier 4- Benign or Likely benign variants. For each computed classification the criteria engaged are displayed along with the supporting evidence.
QCI Interpret for Oncology goes beyond genomic descriptive information to include data on clinical impact (diagnostic, prognostic, predictive), matched drugs available, and therapeutic effect. When searching for appropriate therapeutic options, the actual diagnosis is usually used to match treatments and clinical trials. QCI Interpret for Oncology offers the opportunity to search for treatment and clinical trials even in the case of an unknown diagnosis.
The QIAGEN Knowledge Base contains published articles that refer to the specific variants, along with the categorization of the article types: clinical cases, functional studies, drug labels and guidelines, treatment studies, prognostic studies, reviews, and external database reports.
In QCI Interpret for Oncology you can inspect and evaluate the curated data to make a final decision on the pathogenicity/actionability assessment and reportability status (allow the variant to be displayed on the final clinical report). When vetting the criteria in the Assessment window, you can easily add your own criteria for the final variant assessment.
QCI Interpret for Oncology provides expert test interpretation with the updated new world data from basic research and clinical trials. QIAGEN’s goal is to enable customers to generate real-world insights from increasingly large genomic data sets.
QCI Interpret for Oncology enables you to simultaneously search for both single nucleotide variants (SNVs) and copy number variants (CNVs) in each sample. The software provides an integrative view of the small variations together with large exonic indels. To narrow down the list of variants, you can filter and prioritize them according to actionability.
QCI Interpret for Oncology lists the co-occurring variants in each sample. If the mutations occur in the same gene, the software’s “protein view” shows the presence of the mutations, their positions, and their effect on the protein.
QCI Interpret for Oncology identifies and lists co-occurring variants in each clinical sample, providing evidence on the clinical effect with reference to relevant guidelines. The software allows you to filter variants according to genes in which actionable mutations are detected and to visualize the co-mutations that exist in the sample. Users also receive an expert explanation on the clinical effect of the co-occurring mutations with reference to clinical guidelines.
QCI Interpret for Oncology enables users to easily issue report amendments without needing to run the report again.
QCI Interpret provides a comprehensive and flexible reporting system that automatically incorporates significant variants, key findings, annotation sources, and interpretation summaries. Reports can be fully customized to meet your lab’s brand and formatting requirements. This sample report is for a pan-cancer multimodal panel and shows results with TMB and MSI biomarkers and a KRAS alteration detected.
Discover why QCI Interpret is one of the most trusted clinical bioinformatics platforms in the world.
-Hiroyuki Mano, MD, PhD, Director of C-CAT, National Cancer Center of Japan
